Biopharmaceutical compositions comprising antibody variants
The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
1. A composition comprising,
a. a first antibody comprising a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2; and
b. a first variant form of the first antibody comprising a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 60 of SEQ ID NO: 1 is N or S, position 317 of SEQ ID NO: 1 is N or S, and position 363 of SEQ ID NO: 1 is N or S.
2. The composition of claim 1 , further comprising a second variant form of the first antibody, wherein the second variant form comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 22 of SEQ ID NO: 2 is N or S, position 37 of SEQ ID NO: 2 is N or S, and position 216 of SEQ ID NO: 2 is N or S.
3. The composition of claim 2 , further comprising a third variant form of the first antibody, wherein the third variant form comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 60 of SEQ ID NO: 1 is N or S, position 317 of SEQ ID NO: 1 is N or S, position 363 of SEQ ID NO: 1 is N or S, position 22 of SEQ ID NO: 2 is N or S, position 37 of SEQ ID NO: 2 is N or S and position 216 of SEQ ID NO: 2 is N or S.
4. The composition of claim 2 , wherein the second variant form of the first antibody comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 31 of SEQ ID NO: 2 is N or S, position 34 of SEQ ID NO: 2 is N or S, position 143 of SEQ ID NO: 2 is N or S, position 144 of SEQ ID NO: 2 is N or S, position 158 of SEQ ID NO: 2 is N or S, and position 164 of SEQ ID NO: 2 is N or S.
5. The composition of claim 4 , wherein the first variant form of the first antibody comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 76 of SEQ ID NO: 1 is N or S, position 84 of SEQ ID NO: 1 is N or S, position 161 of SEQ ID NO: 1 is N or S, position 203 of SEQ ID NO: 1 is N or S, position 205 of SEQ ID NO: 1 is N or S, position 210 of SEQ ID NO: 1 is N or S, position 278 of SEQ ID NO: 1 is N or S, position 288 of SEQ ID NO: 1 is N or S, position 386 of SEQ ID NO: 1 is N or S, position 391 of SEQ ID NO: 1 is N or S, position 392 of SEQ ID NO: 1 is N or S, position 423 of SEQ ID NO: 1 is N or S and position 436 of SEQ ID NO: 1 is N or S.
6. The composition of claim 1 , further comprising a third variant form of the first antibody, wherein the third variant form comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 60 of SEQ ID NO: 1 is N or S, position 317 of SEQ ID NO: 1 is N or S position 363 of SEQ ID NO: 1 is N or S, position 22 of SEQ ID NO: 2 is N or S, position 37 of SEQ ID NO: 2 is N or S and position 216 of SEQ ID NO: 2 Ss.
7. The composition of claim 6 , wherein the third variant form of the first antibody comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 76 of SEQ ID NO: 1 is N or S, position 84 of SEQ ID NO: 1 is N or S, position 161 of SEQ ID NO: 1 is N or S, position 203 of SEQ ID NO: 1 is N or S, position 205 of SEQ ID NO: 1 is N or S, position 210 of SEQ ID NO: 1 is N or S, position 278 of SEQ ID NO: 1 is N or S, position 288 of SEQ ID NO: 1 is N or S, position 386 of SEQ ID NO: 1 is N or S, position 391 of SEQ ID NO: 1 is N or S, position 392 of SEQ ID NO: 1 is N or S, position 423 of SEQ ID NO: 1 is N or S, position 436 of SEQ ID NO: 1 is N or S, position 31 of SEQ ID NO: 2 is N or S, position 34 of SEQ ID NO: 2 is N or S, position 143 of SEQ ID NO: 2 is N or S, position 144 of SEQ ID NO: 2 is N or S, position 158 of SEQ ID NO: 2 is N or S, and position 164 of SEQ ID NO: 2 is N or S.
8. The composition of claim 1 , wherein the first variant form of the first antibody comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 76 of SEQ ID NO: 1 is N or S, position 84 of SEQ ID NO: 1 is N or S, position 161 of SEQ ID NO: 1 is N or S, position 203 of SEQ ID NO: 1 is N or S, position 205 of SEQ ID NO: 1 is N or S, position 210 of SEQ ID NO: 1 is N or S, position 278 of SEQ ID NO: 1 is N or S, position 288 of SEQ ID NO: 1 is N or S, position 386 of SEQ ID NO: 1 is N or S, position 391 of SEQ ID NO: 1, position 392 of SEQ ID NO: 1 is N or S, position 423 of SEQ ID NO: 1 is N or S, and position 436 of SEQ ID NO: 1 is N or S.
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 1 .
10. A composition comprising,
a. a first antibody comprising a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2; and
b. a first variant form of the first antibody comprising a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 22 of SEQ ID NO: 2 is N or S, position 37 of SEQ ID NO: 2 is N or S, and position 216 of SEQ ID NO: 2 is N or S.
11. The composition of claim 10 , wherein the first variant form of the first antibody further comprises position 31 of SEQ ID NO: 2 is N or S, position 34 of SEQ ID NO: 2 is N or S, position 143 of SEQ ID NO: 2 is N or S, position 144 of SEQ ID NO: 2 is N or S, position 158 of SEQ ID NO: 2 is N or S, and position 164 of SEQ ID NO: 2 is N or S.
12. The composition of claim 10 , further comprising a third variant form of the first antibody, wherein the third variant comprises a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein comprising position 60 of SEQ ID NO: 1 is N or S, position 317 of SEQ ID NO: 1 is N or S position 363 of SEQ ID NO: 1 is N or S, position 22 of SEQ ID NO: 2 is N or S, position 37 of SEQ ID NO: 2 is N or S, and position 216 of SEQ ID NO: 2 is N or S.
13. The composition of claim 12 , wherein the third variant form of the first antibody further comprises position 76 of SEQ ID NO: 1 is N or S, position 84 of SEQ ID NO: 1 is N or S, position 161 of SEQ ID NO: 1 is N or S, position 203 of SEQ ID NO: 1 is N or S, position 205 of SEQ ID NO: 1 is N or S, position 210 of SEQ ID NO: 1 is N or S, position 278 of SEQ ID NO: 1 is N or S, position 288 of SEQ ID NO: 1 is N or S, position 386 of SEQ ID NO: 1 is N or S, position 391 of SEQ ID NO: 1 is N or S, position 392 of SEQ ID NO: 1 is N or S, position 423 of SEQ ID NO: 1 is N or S, position 436 of SEQ ID NO: 1 is N or S, position 31 of SEQ ID NO: 2 is N or S, position 34 of SEQ ID NO: 2 is N or S, position 143 of SEQ ID NO: 2 is N or S, position 144 of SEQ ID NO: 2 is N or S, position 158 of SEQ ID NO: 2 is N or S and position 164 of SEQ ID NO: 2 is N or S.
14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 10 .
15. A composition comprising,
a. a first antibody comprising a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2; and
b. a first variant form of the first antibody comprising a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2, wherein position 60 of SEQ ID NO: 1 is N or S, position 317 of SEQ ID NO: 1 is N or S, position 363 of SEQ ID NO: 1 is N or S, position 22 of SEQ ID NO: 2 is N or S, position 37 of SEQ ID NO: 2 is N or S, and position 216 of SEQ ID NO: 2 is N or S.
16. The composition of claim 15 , wherein the first variant form of the first antibody further comprises position 76 of SEQ ID NO: 1 is N or S, position 84 of SEQ ID NO: 1 is N or S, position 161 of SEQ ID NO: 1 is N or S, position 203 of SEQ ID NO: 1 is N or S, position 205 of SEQ ID NO: 1 is N or S, position 210 of SEQ ID NO: 1 is N or S, position 278 of SEQ ID NO: 1 is N or S, position 288 of SEQ ID NO: 1 is N or S, position 386 of SEQ ID NO: 1 is N or S, position 391 of SEQ ID NO: 1 is N or S, position 392 of SEQ ID NO: 1 is N or S, position 423 of SEQ ID NO: 1 is N or S, and position 436 of SEQ ID NO: 1 is N or S.
17. The composition of claim 16 , wherein the first variant form of the first antibody further comprises position 31 of SEQ ID NO: 2 is N or S, position 34 of SEQ ID NO: 2 is N or S, position 143 of SEQ ID NO: 2 is N or S, position 144 of SEQ ID NO: 2 is N or S, position 158 of SEQ ID NO: 2 is N or S and position 164 of SEQ ID NO: 2 is N or S.
18. The composition of claim 15 , wherein the first variant form of the first antibody further comprises position 31 of SEQ ID NO: 2 is N or S, position 34 of SEQ ID NO: 2 is N or S, position 143 of SEQ ID NO: 2 is N or S, position 144 of SEQ ID NO: 2 is N or S, position 158 of SEQ ID NO: 2 is N or S, and position 164 of SEQ ID NO: 2 is N or S.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 15 .